search
Back to results

Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection

Primary Purpose

Helicobacter Pylori Infection

Status
Unknown status
Phase
Phase 4
Locations
Taiwan
Study Type
Interventional
Intervention
ET
SGT
Sponsored by
National Taiwan University Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Helicobacter Pylori Infection focused on measuring Helicobacter pylori,Susceptibility testing,empirical,third-line treatment

Eligibility Criteria

20 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion criteria

  • Adult (equal or greater than 20 years old) patients who failed from at least two eradication therapies for H. pylori infection will be enrolled.

Sites / Locations

  • National Taiwan University HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

(B) Empirical therapy

(A) Susceptibility testing guided therapy

Arm Description

choose antibiotics according to drug history

choose antibiotics according to susceptibility testing

Outcomes

Primary Outcome Measures

The primary outcome is the eradication rate in the third treatment according to intention-to treat (ITT) analysis.
Eradication rate will be determined by urea breath test at least 6 weeks after completion of treatment.

Secondary Outcome Measures

Adverse effects
A standard interview and questionaire will be used to assess the adverse effects.

Full Information

First Posted
April 1, 2020
Last Updated
January 14, 2021
Sponsor
National Taiwan University Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04332848
Brief Title
Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection
Official Title
Comparison of Susceptibility Testing Guided Versus Empirical Therapy for the Third-line Eradication of H. Pylori- a Multicenter Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2021
Overall Recruitment Status
Unknown status
Study Start Date
July 24, 2020 (Actual)
Primary Completion Date
March 2023 (Anticipated)
Study Completion Date
March 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Taiwan University Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Aim: Therefore, we aimed to compare the efficacy of susceptibility testing guided therapy vs. empirical therapy in the third-line eradication for refractory H. pylori infection assess the long-term impact of eradication therapy on the antibiotic resistance and microbiota of the gut flora and the metabolic factors. Methods: This will be a multi-center, open labeled trial Patients: 360 patients with failure to H. pylori eradication for at least two times will be enrolled Determination of antibiotic resistance of H. pylori: Agar dilution test will be used to determine the minimum inhibitory concentrations of levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of antibiotics. Treatment regimens and assignment: Eligible patients will be randomized to receive either one of the treatments (A) Susceptibility testing guided therapy or (B) Empirical therapy Outcome Measurement: Primary End Point: Eradication rate will be evaluated according to Intent-to-treat (ITT) analyses. Secondary End Point: 1. Eradication rate according to per protocol analysis (PP analysis); 2. Frequency of adverse effects.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Helicobacter Pylori Infection
Keywords
Helicobacter pylori,Susceptibility testing,empirical,third-line treatment

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
360 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
(B) Empirical therapy
Arm Type
Experimental
Arm Description
choose antibiotics according to drug history
Arm Title
(A) Susceptibility testing guided therapy
Arm Type
Active Comparator
Arm Description
choose antibiotics according to susceptibility testing
Intervention Type
Drug
Intervention Name(s)
ET
Intervention Description
Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Intervention Type
Drug
Intervention Name(s)
SGT
Intervention Description
Susceptibility testing guided therapy Based on susceptibility test: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin triple therapy or concomitant therapy
Primary Outcome Measure Information:
Title
The primary outcome is the eradication rate in the third treatment according to intention-to treat (ITT) analysis.
Description
Eradication rate will be determined by urea breath test at least 6 weeks after completion of treatment.
Time Frame
6 weeks
Secondary Outcome Measure Information:
Title
Adverse effects
Description
A standard interview and questionaire will be used to assess the adverse effects.
Time Frame
2 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria Adult (equal or greater than 20 years old) patients who failed from at least two eradication therapies for H. pylori infection will be enrolled.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Mei-Jyh Chen
Phone
886-2-23123456
Ext
66280
Email
migichen@ntuh.gov.tw
First Name & Middle Initial & Last Name or Official Title & Degree
Yu-Chun Huang
Email
nneder34@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Mei-Jyh Chen, MD
Organizational Affiliation
National Taiwan University Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Taiwan University Hospital
City
Taipei
ZIP/Postal Code
10002
Country
Taiwan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mei-Jyh Chen, MD

12. IPD Sharing Statement

Learn more about this trial

Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection

We'll reach out to this number within 24 hrs